Zhengye Biotechnology releases 2026 chairman letter outlining growth plans
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders
February 10, 2026 8:30 AM ESTJilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the Company or Zhengye), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that Mr. Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. In the letter, Mr. Han highlights the Companys research and operational milestones achieved in 2025 and outlines Zhengyes strategic priorities for growth in 2026. The full text of the letter follows.
... More